World-renowned expert in thrombosis and blood clotting, Alex C. Spyropoulos, MD, Professor at the Institute of Health System Science at the Feinstein Institutes for Medical Research and Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, has been selected for a prestigious Fulbright United States Scholar award for the 2026-2027 academic year from the U.S. Department of State and the Fulbright Foreign Scholarship Board. This esteemed recognition will foster Dr. Spyropoulos’ engagement in international research and collaboration, further advancing global health and medical education.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505085862/en/
Dr. Alex C. Spyropoulos has been honored as a prestigious Fulbright U.S. Scholar. (Credit: Feinstein Institutes)
The Fulbright Program, the U.S. government’s flagship international educational exchange program, aims to increase mutual understanding between the people of the U.S. and other countries. Since its inception in 1946, nearly 450,000 individuals have participated in the program. As a Fulbright Scholar, Dr. Spyropoulos will join a network of alumni that includes 62 Nobel Laureates, 93 Pulitzer Prize winners, 82 MacArthur Fellows, 44 heads of state or government, and thousands of leaders across the private, public and nonprofit sectors.
Fulbright is a program of the State Department, with funding provided by the federal government. Participating governments and host institutions, corporations and foundations around the world also provide direct and indirect support to the program, which operates in over 160 countries worldwide for over 800 individuals to teach or conduct research abroad through the Fulbright U.S. Scholar Program each year.
“I am incredibly honored and humbled to be selected as a Fulbright U.S. Scholar,” said Dr. Spyropoulos. “This opportunity represents a unique chance to foster international collaboration, share knowledge gleaned from our work and collectively push the boundaries of medical science, particularly in the critical area of thrombosis and anticoagulation. I look forward to contributing to global health initiatives and promoting cross-cultural scientific exchange.”
Dr. Spyropoulos is internationally recognized for his groundbreaking research in anticoagulation, particularly in the prevention and treatment of venous thromboembolism (VTE), the appropriate use of direct oral anticoagulants (DOACs), and the perioperative management of patients on antithrombotic therapy. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.
His extensive contributions include leading or co-leading pivotal global multicenter randomized trials such as the landmark NIH-funded BRIDGE trial on perioperative bridging anticoagulation, the PAUSE trial for perioperative use of direct oral anticoagulants, the MARINER trial for extended thromboprophylaxis in hospitalized medical patients, and the PREVENT-HD trial on thromboprophylaxis in COVID-19 outpatients. Dr. Spyropoulos was also the principal investigator of the HEP-COVID trial, which determined optimal heparin dose in hospitalized COVID-19 patients, and the CORE-19 registry, one of the largest registries assessing thromboembolic outcomes in hospitalized COVID-19 patients. Dr. Spyropoulos’s findings have been published in over 330 peer-reviewed journals.
“Dr. Spyropoulos’ dedication to advancing medical knowledge has had a profound impact on patient care,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes, Karches Family Distinguished Chair in Medical Research. “His selection as a Fulbright Scholar is a testament to his exceptional contributions, commitment to groundbreaking research and global collaboration.”
Last month, Dr. Spyropoulos co-authored an editorial in the New England Journal of Medicine (NEJM) discussing how clinicians approach intermediate-risk pulmonary embolism. The article highlighted findings from the HI-PEITHO trial, showcasing ultrasound-facilitated, catheter-directed thrombolysis (CDT) as a significantly more effective and safer treatment option. This groundbreaking therapy dramatically reduces adverse outcomes like PE-related death and cardiac decompensation without increasing the risk of major bleeding, marking a pivotal advancement for patients with this serious cardiovascular condition.
About the Feinstein Institutes
The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260505085862/en/
Media gallery
